Table II.
Clinical characteristics of the validation set.
| OS, months | OS, % | |||||
|---|---|---|---|---|---|---|
| Characteristic | No. of patients | Median | 95% CI | 3-year | 5-year | Log-rank P-value |
| Age | ||||||
| ≤60 | 1,041 | 30 | 24.54–34.54 | 45.7±1.8 | 34.6±2.1 | <0.001 |
| >60 | 3,559 | 21 | 19.68–22.31 | 34.6±1.0 | 23.7±1.1 | |
| Sex | ||||||
| Male | 2,507 | 20 | 18.77–21.22 | 31.7±1.1 | 22.3±1.2 | <0.001 |
| Female | 2,093 | 28 | 25.31–30.69 | 43.9±1.3 | 31.3±1.6 | |
| Marital status | ||||||
| Married | 2,519 | 26 | 24.01–27.98 | 41.8±1.2 | 30.0±1.3 | <0.001 |
| Unmarried | 2,081 | 20 | 18.44–21.55 | 31.5±1.2 | 21.5±1.4 | |
| Race | ||||||
| Caucasian | 3,713 | 22 | 20.68–23.32 | 36.8±0.9 | 26.1±1.1 | 0.035 |
| African-American | 547 | 22 | 19.31–24.68 | 35.2±2.5 | 26.3±2.7 | |
| Other | 340 | 31 | 25.94–36.05 | 44.2±3.4 | 25.4±3.9 | |
| Histology | ||||||
| ADC | 2,420 | 31 | 28.66–33.33 | 41.8±1.2 | 30.0±1.3 | <0.001 |
| SCC | 2,026 | 16 | 14.69–17.30 | 28.1±1.2 | 19.1±1.3 | |
| LCC | 103 | 30 | 18.56–41.43 | 43.9±5.8 | 33.4±6.1 | |
| ASC | 31 | 15 | 7.23–22.77 | 31.5±1.2 | 21.5±1.4 | |
| Grade | ||||||
| I | 370 | 41 | 30.81–51.18 | 52.0±3.1 | 40.1±3.9 | <0.001 |
| II | 1,837 | 26 | 23.79–28.20 | 40.7±1.4 | 27.4±1.6 | |
| III | 2,334 | 19 | 17.62–20.37 | 32.2±1.2 | 23.0±1.2 | |
| IV | 59 | 20 | 9.21–30.78 | 37.2±7.1 | 30.1±7.4 | |
| AJCC (7th) T stage (45) | ||||||
| T1 | 601 | 37 | 28.94–45.05 | 50.9±2.4 | 35.1±3.0 | <0.001 |
| T2 | 1,718 | 25 | 22.64–27.35 | 39.6±1.4 | 27.3±1.6 | |
| T3 | 1,444 | 23 | 21.08–24.91 | 36.5±1.5 | 26.0±1.7 | |
| T4 | 837 | 13 | 11.45–14.54 | 23.4±1.8 | 16.0±1.9 | |
| AJCC (7th) N stage (45) | ||||||
| N0 | 1,433 | 30 | 26.09–33.90 | 45.6±1.6 | 35.4±1.9 | <0.001 |
| N1 | 990 | 34 | 29.35–38.46 | 48.7±1.9 | 32.3±2.3 | |
| N2 | 1,848 | 18 | 16.68–19.32 | 27.9±1.2 | 18.6±1.3 | |
| N3 | 329 | 13 | 10.62–15.37 | 19.7±2.8 | 4.5±3.5 | |
| Primary site | ||||||
| Main bronchus | 118 | 14 | 9.43–18.57 | 18.1±4.4 | 12.1±5.7 | <0.001 |
| Upper lobe | 2,869 | 22 | 20.46–23.53 | 37.0±1.1 | 25.4±1.2 | |
| Middle lobe | 181 | 22 | 17.03–26.96 | 36.2±4.3 | 32.2±4.7 | |
| Lower lobe | 1,432 | 25 | 22.55–27.48 | 39.2±1.6 | 28.6±1.8 | |
| Laterality | ||||||
| Left | 1,913 | 23 | 20.98–25.01 | 37.7±1.3 | 26.2±1.5 | 0.932 |
| Right | 2,687 | 23 | 21.48–24.51 | 36.8±1.1 | 26.4±1.2 | |
| Surgery | ||||||
| None | 2,433 | 13 | 12.23–13.77 | 17.9±1.0 | 9.4±1.0 | <0.001 |
| Wedge resection | 163 | 35 | 26.19–43.80 | 47.8±5.0 | 30.7±6.5 | |
| Segmental resection | 45 | 31 | 24.01–37.98 | 46.9±9.1 | 37.5±9.4 | |
| Lobectomy | 1,959 | 50 | 44.69–55.03 | 60.0±1.3 | 45.3±1.6 | |
| Lymph node dissection | ||||||
| None | 2,398 | 13 | 12.20–13.79 | 18.3±1.0 | 10.1±1.0 | <0.001 |
| 1–3 | 306 | 35 | 29.49–40.51 | 46.5±3.4 | 29.2±4.2 | |
| ≥4 | 1,896 | 50 | 44.13–55.87 | 59.5±1.4 | 45.4±1.7 | |
| Radiation | ||||||
| No | 2,176 | 19 | 17.75–20.25 | 28.6±1.2 | 19.3±1.2 | <0.001 |
| Yes | 2,424 | 30 | 27.34–32.65 | 44.9±1.2 | 32.7±1.4 | |
| Chemotherapy | ||||||
| No | 1,812 | 18 | 16.04–19.96 | 33.9±1.3 | 24.9±1.5 | <0.001 |
| Yes | 2,788 | 25 | 23.32–26.67 | 39.3±1.1 | 27.3±1.3 | |
OS, overall survival; ADC, adenocarcinoma; SCC, squamous cell carcinoma; LCC, large cell carcinoma; ASC, adenosquamous carcinoma; AJCC (7th), American Joint Committee on Cancer.